| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 173,85 | 174,15 | 14:11 | |
| 173,55 | 174,15 | 14:09 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 175,70 | 197 | |||
| 175,55 | 7 | |||
| 175,50 | 200 | |||
| 175,40 | 300 | |||
| 175,15 | 7 | |||
| 175,00 | 44 | |||
| 174,95 | 6 | |||
| 174,45 | 47 | |||
| 174,40 | 80 | |||
| 174,35 | 47 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/4ab.htm [/URL] | ||||
| 47 | 173,75 | |||
| 40 | 173,70 | |||
| 86 | 173,60 | |||
| 127 | 173,55 | |||
| 200 | 173,20 | |||
| 7 | 172,90 | |||
| 300 | 172,80 | |||
| 148 | 172,60 | |||
| 1 | 172,55 | |||
| 73 | 172,50 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.029 | 0,909 | 935 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 13:34:30 | 173,90 | 47 |
| 13:28:27 | 174,85 | 45 |
| 13:28:27 | 174,80 | 47 |
| 13:26:59 | 174,85 | 92 |
| 12:14:49 | 174,15 | 13 |
| 12:14:49 | 174,15 | 3 |
| 11:36:51 | 175,20 | 41 |
| 10:00:51 | 174,45 | 15 |
| 10:00:51 | 174,40 | 47 |
| 10:00:51 | 174,05 | 1 |
| 09:57:57 | 172,45 | 7 |
| 09:57:57 | 172,45 | 127 |
| 09:05:24 | 173,80 | 21 |
| 09:05:24 | 173,80 | 6 |
| 09:05:24 | 173,80 | 21 |
| 09:04:34 | 173,80 | 46 |
| Tagesumsatz Xetra | -0,70 -0,40 % | 649 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:36 | AbbVie Announces Founding Sponsorship Of BioLabs University Of Toronto | 277 | AFX News | WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced the expansion of its partnership with BioLabs by becoming the founding sponsor of the new BioLabs University of Toronto. The AbbVie and BioLabs... ► Artikel lesen | |
| Mo | AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada | 6 | CNW | ||
| Mo | AbbVie launches 'PSO Done' psoriasis campaign with cross-agency effort | 22 | FiercePharma | ||
| Mo | Nxera Pharma To Receive $10 Mln Milestone Payment From AbbVie Under Neurology Collaboration | 273 | AFX News | TOKYO (dpa-AFX) - Nxera Pharma Co., Ltd. (4565.T, SOLTF), a research-based biopharmaceutical company, on Monday announced that it will receive a $10 million milestone payment from AbbVie Inc.... ► Artikel lesen | |
| ABBVIE Aktie jetzt für 0€ handeln | |||||
| Mo | Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases | 95 | GlobeNewswire (Europe) | This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipelineUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 08:48 | FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus | Business Wire | FDA ACCEPTS APPLICATION FOR GENENTECH'S GAZYVA FOR THE TREATMENT OF THE MOST COMMON FORM OF LUPUS Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction... ► Artikel lesen | |
| 11:06 | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca nach Studiendaten auf "Overweight" mit einem Kursziel von 16000 Pence belassen. Der Pharmakonzern habe positive... ► Artikel lesen | |
| 12:02 | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness Signs Second Franchise Agreement for the City of Ottawa, Ontario | Newsfile | Toronto, Ontario--(Newsfile Corp. - April 21, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| 09:51 | Trumps Psychedelika-Dekret: Goldrausch für Bioxyne und Co.? Diese drei Aktien stehen jetzt im Fokus | Small- & Micro Cap Investment | ||
| 12:30 | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Tubulis GmbH, Planegg-Martinsried | Bundeskartellamt | Datum der Anmeldung:19.04.2026Aktenzeichen:B3-57/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Tubulis GmbH, Planegg-MartinsriedProduktmärkte:Antikörper-Wirkstoff-Konjugate... ► Artikel lesen |